Zhaoke Ophthalmology-B (06622) announced results for the year ended December 31, 2023, and the group achieved revenue...
According to the Zhitong Finance App, Zhaoke Ophthalmology-B (06622) announced the results for the year ended December 31, 2023. The group obtained revenue of RMB 18.75 million (same unit), with zero revenue for the same period last year; R&D expenses of RMB 333 million, up 12.35% year on year; loss of 385 million yuan during the year, down 5.5% year on year; adjusted loss of 363 million yuan, up 0.66% year on year; loss per share.
In 2023, the company obtained a total revenue of 18.8 million yuan, of which 4.7 million yuan came from the sale of ophthalmic drugs (including bemesil, timolol and Rubotel), and 8.4 million yuan from sales of over-the-counter ophthalmic products (Baudex series hot eye masks). Additionally, the company obtained 5.6 million yuan in revenue from distribution transaction payments outside of China.